New study tracks Real-World use of upadacitinib for ulcerative colitis in china

NCT ID NCT06838845

First seen Nov 26, 2025 · Last updated Apr 26, 2026 · Updated 13 times

Summary

This study follows about 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will track how well the drug controls symptoms like bloody diarrhea over one year, using only routine checkup data. The goal is to see how effective this approved treatment is in a real-world Chinese population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997

    RECRUITING

    Guangzhou, Guangdong, 510080, China

  • The Second Affiliated Hospital Of Zhengzhou University /ID# 274754

    RECRUITING

    Zhengzhou, Henan, 450014, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753

    RECRUITING

    Guangzhou, Guangdong, 510655, China

Conditions

Explore the condition pages connected to this study.